Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics to Present at Jefferies 2017

RNS Number: 2495W Allergy Therapeutics PLC 13 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference 13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces th...

Director/PDMR Shareholding

RNS Number: 8138V Allergy Therapeutics PLC 07 November 2017 The announcement released by Allergy Therapeutics plcentitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as 0.0001 per share. The correct exercise price is 0.001. All other figures remain unchanged. The correct figure is included in the reissued ann...

Director/PDMR Shareholding

RNS Number: 8006V Allergy Therapeutics PLC 07 November 2017 07 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Grant of Options under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance c...

Publication of Annual Report and notice of AGM

RNS Number: 1267U Allergy Therapeutics PLC 19 October 2017 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING Allergy Therapeutics Plc has today published the following documents: Annual Report for the year ended 30 June 201...

All News

DateHeadlineSource
24-03-14Allergy grows profits StockMarketWire
24-03-14Half Yearly ReportRNS
17-03-14Notice of ResultsRNS
12-03-14Shareholder updateRNS
19-02-14Health Canada approves Allergy CTA submission StockMarketWire
19-02-14Health Canada approves submission of CTARNS
11-02-14Holding(s) in CompanyRNS
27-01-14Allergy Therapeutics study results publishedStockMarketWire
27-01-14Results published in highly respected journalRNS
14-01-14Allergy Therapeutics revenues up 12%StockMarketWire
14-01-14Trading Update and Notice of ResultsRNS
20-11-13Allergy Therapeutics resolutions passed at AGMStockMarketWire
20-11-13Result of AGMRNS
20-11-13Allergy Therapeutics appoints R&D directorStockMarketWire
20-11-13Allergy Therapeutics revenues upStockMarketWire
20-11-13Business and R&D UpdateRNS
09-10-13Notification under AIM Rule Schedule Two (g)RNS
27-09-13Allergy Therapeutics appoints adviser StockMarketWire
27-09-13Change of AdviserRNS
19-09-13Holding(s) in CompanyRNS
16-09-13Allergy Therapeutics improves market shareStockMarketWire
16-09-13Final ResultsRNS
15-08-13Allergy Therapeutics schedules FY results StockMarketWire
15-08-13Notice of results and shareholder updateRNS
03-06-13Holding(s) in CompanyRNS
15-05-13Grant of OptionsRNS
08-05-13Holding(s) in CompanyRNS
08-05-13Holding(s) in CompanyRNS
25-03-13Half Yearly ReportRNS
11-03-13Allergy Therapeutics granted US patent StockMarketWire
11-03-13US patent grantedRNS
11-03-13Notice of results and shareholder updateRNS
01-02-13Total Voting RightsRNS
22-01-13Exercise of OptionsRNS
28-12-12Total Voting RightsRNS
27-12-12Update on Lincoln Medical FinalRNS
19-12-12Grant of OptionsRNS
10-12-12Director/PDMR ShareholdingRNS
05-12-12Total Voting RightsRNS
04-12-12Exercise of OptionsRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account